PMID- 36662602
OWN - NLM
STAT- MEDLINE
DCOM- 20230303
LR  - 20230315
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Linking)
VI  - 23
IP  - 2
DP  - 2023 Feb
TI  - Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin 
      lymphoma.
PG  - 121-126
LID - 10.1080/14737140.2023.2171397 [doi]
AB  - INTRODUCTION: Chimeric antigen receptor T (CAR T) cell therapy epitomizes the 
      success of T cell engineering. Today, it is an integral component of the 
      treatment algorithm for various types of B-cell non-Hodgkin lymphoma (NHL). Large 
      B-cell lymphoma (LBCL) is the most common subtype of NHL accounting for 30-35% of 
      cases. A lack of response to second-line therapy portends a poor prognosis as 
      only 7-15% of patients attain complete remission (CR) with subsequent 
      conventional chemoimmunotherapy. AREAS COVERED: Lisocabtagene maraleucel 
      (liso-cel) is an autologous CD-19 directed CAR T-cell product with a 4-1BB 
      co-stimulatory domain administered as a sequential infusion of 2 separately 
      manufactured components: CD8(+) and CD4(+) CAR T-cells in equal doses. Liso-cel 
      showed an impressive objective response rate of 73% (CR = 53%) in patients who 
      had received a median of 3 prior therapies. Median time-to-first CR or partial 
      response (PR) was 1 month. EXPERT OPINION: When evaluated in the second line 
      setting in LBCL, liso-cel demonstrated superior event-free survival (EFS) versus 
      standard of care. While acknowledging that choice of a particular CAR T-cell is 
      based chiefly on familiarity of the treating physician with a specific product, 
      liso-cel definitely represents an important addition to the treatment 
      armamentarium of R/R LBCL whether in the second-line setting or beyond.
FAU - Mohty, Razan
AU  - Mohty R
AD  - Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular 
      Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
AD  - Department of Blood and Marrow Transplantation and Cellular Immunotherapy, 
      Moffitt Cancer Center, Tampa, FL, USA.
FAU - Moreno Vanegas, Yenny
AU  - Moreno Vanegas Y
AD  - Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular 
      Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
FAU - Chavez, Julio C
AU  - Chavez JC
AD  - Department of Blood and Marrow Transplantation and Cellular Immunotherapy, 
      Moffitt Cancer Center, Tampa, FL, USA.
FAU - Kharfan-Dabaja, Mohamed A
AU  - Kharfan-Dabaja MA
AUID- ORCID: 0000-0001-7394-5185
AD  - Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular 
      Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
LA  - eng
PT  - Journal Article
DEP - 20230124
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - Humans
MH  - *Lymphoma, Large B-Cell, Diffuse/therapy
MH  - *Receptors, Chimeric Antigen
MH  - Immunotherapy, Adoptive
MH  - T-Lymphocytes
MH  - Immunotherapy
OTO - NOTNLM
OT  - Lisocabtagene maraleucel
OT  - chimeric antigen receptor T-cell therapy
OT  - large B cell lymphoma
OT  - overall survival
OT  - response rates
EDAT- 2023/01/21 06:00
MHDA- 2023/03/04 06:00
CRDT- 2023/01/20 12:22
PHST- 2023/01/21 06:00 [pubmed]
PHST- 2023/03/04 06:00 [medline]
PHST- 2023/01/20 12:22 [entrez]
AID - 10.1080/14737140.2023.2171397 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2023 Feb;23(2):121-126. doi: 
      10.1080/14737140.2023.2171397. Epub 2023 Jan 24.